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Introduction: Febuxostat is a non-purine-selective oral xanthine oxidase inhibitor drug, 
and is an alternative to Allopurinol to lower serum uric acid in gout patients. It is 
probably more effective than Allopurinol, however, its use is limited because of its cost 
and availability. Allopurinol has been the mainstay treatment for gout for about 50 
years. However, its use has been associated with allergic reactions especially in patients 
with renal impairment.The objective of this study was to describe HTAA Rheumatology 
Unit experiences with Febuxostat in the management of gout.  
Materials and method: Case records belonging to 6 patients who had been started on 
Febuxostat between January 2012 and January 2017 were analysed.  
Results: The majority of patients on Febuxostat were males (83.3%) as well as Malays 
(83.3%). About 66.7% of patients had already developed mild to moderate chronic kidney 
disease (GFR between 30-89 mL/min) due to multifactorial causes by the time they were 
started on Febuxostat. Also 33% of patients had mild liver impairment (ALT & AST < 1.5 
ULN) due to fatty liver prior to Febuxostat. All patients had been started on Febuxostat 
due to allergic reactions to Allopurinol. All patients were on Febuxostat 40 mg once a 
day. Following Febuxostat, a significant decrease in the uric acid levels much closer to 
the target level i.e. less than 360 µmol/L were achieved in all patients. Only 1 patient 
(16.7%) developed a side effect i.e. ALT > 1.5 ULN while the rest tolerated the drug very 
well.  
Conclusion: Although the number of patients analysed was small, Febuxostat was shown 
to be very effective and safe for use in patients with gout even with concomitant mild 
to moderate renal impairment. Serum uric acid levels reduced significantly while on the 
lowest dose of 40 mg once a day. 
  
